These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28927716)

  • 21. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomised trial of three counselling strategies for lifestyle changes in patients with hypercholesterolemia treated with ezetimibe on top of statin therapy (TWICE).
    Steg PG; Verdier JC; Carré F; Darne B; Ducardonnet A; Jullien G; Farnier M; Giral P; Haïat R;
    Arch Cardiovasc Dis; 2008; 101(11-12):723-35. PubMed ID: 19059567
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins and almonds to lower lipoproteins (the STALL Study).
    Ruisinger JF; Gibson CA; Backes JM; Smith BK; Sullivan DK; Moriarty PM; Kris-Etherton P
    J Clin Lipidol; 2015; 9(1):58-64. PubMed ID: 25670361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased statin dose could mean a 22% decrease in vascular events. Even patients with low baseline LDL can benefit from increased doses.
    Duke Med Health News; 2011 Jan; 17(1):3. PubMed ID: 21313727
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012.
    Wong ND; Young D; Zhao Y; Nguyen H; Caballes J; Khan I; Sanchez RJ
    J Clin Lipidol; 2016; 10(5):1109-18. PubMed ID: 27678427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.
    Candrilli SD; Manjunath R; Davis KL; Gidal BE
    Epilepsy Res; 2010 Oct; 91(2-3):260-6. PubMed ID: 20801617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital.
    Spighi A; Tartagni E; D'Addato S; Dormi A; Borghi C
    J Cardiovasc Med (Hagerstown); 2013 Apr; 14(4):270-5. PubMed ID: 22728834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Among statin-treated patients, LDL, non-HDL and apoB cholesterol biomarkers were associated with increased risks of cardiovascular events.
    Sniderman AD; Thanassoulis G
    Evid Based Med; 2013 Apr; 18(2):73-4. PubMed ID: 22893654
    [No Abstract]   [Full Text] [Related]  

  • 35. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
    Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
    Shishehbor MH; Aviles RJ; Brennan ML; Fu X; Goormastic M; Pearce GL; Gokce N; Keaney JF; Penn MS; Sprecher DL; Vita JA; Hazen SL
    JAMA; 2003 Apr; 289(13):1675-80. PubMed ID: 12672736
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis.
    Shiffman D; Arellano AR; Caulfield MP; Louie JZ; Bare LA; Devlin JJ; Melander O
    BMC Cardiovasc Disord; 2016 Dec; 16(1):251. PubMed ID: 27927162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.